SCHEMBL12349672

SCHEMBL12349672

c1ccc(-c2cccc(-n3c(-c4ccc(-c5cccc6c5oc5ccccc56)cc4)nc4ccccc43)c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
ALOX5 P09917 2/20 0.43
GAA P10253 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 3/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 2/20 0.39
HSP90AA1 P07900 1/20 0.39
RECQL P46063 1/20 0.39
PDE10A Q9Y233 1/20 0.39
GRIA1 P42261 1/20 0.38
CACNG8 Q8WXS5 1/20 0.38
CACNG2 Q9Y698 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
GGPS1 O95749 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15446562 0.94 ESR1 (0.44) ESR1ESR2ALOX5GAAMEN1
SCHEMBL23169658 0.94 ESR1 (0.44) ESR1ESR2ALOX5GAAMEN1
SCHEMBL15393872 0.93 ESR1 (0.43) ESR1ESR2ALOX5GAAMEN1
SCHEMBL12349691 0.93 ESR1 (0.52) ESR1ESR2ALOX5GAAMEN1
SCHEMBL1994838 0.92 ESR1 (0.48) ESR1ESR2ALOX5GAAMEN1
SCHEMBL9288668 0.91 ESR1 (0.43) ESR1ESR2ALOX5GAAMEN1
SCHEMBL23169665 0.90 ESR1 (0.46) ESR1ESR2ALOX5GAAMEN1
SCHEMBL9290148 0.90 PTGER4 (0.41) ESR1ESR2ALOX5GAAMEN1
SCHEMBL9288680 0.90 PTGER4 (0.41) ESR1ESR2ALOX5GAAMEN1
SCHEMBL15394231 0.90 ESR1 (0.44) ESR1ESR2GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2662369-B1 Benzimidazol-2-yl-phenyl compound, light-emitting element, light-emitting device, electronic device, and lighting device SEMICONDUCTOR ENERGY LAB (JP) 2015-09-23 EP disclosed
EP-2662369-A1 benzimidazol-2-yl-phenyl compound, light-emitting element, light-emitting device, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-11-13 EP disclosed
US-8354542-B2 Heterocyclic compound, light-emitting element, light-emitting device, electronic device and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-01-15 US disclosed
US-8354542-B2 Heterocyclic compound, light-emitting element, light-emitting device, electronic device and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2013-01-15 US disclosed
EP-2354135-A1 benzimidazol-2-yl-phenyl compound, light-emitting element, light-emitting device, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-08-10 EP disclosed
US-20110147792-A1 Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2011-06-23 US disclosed
US-20110147792-A1 Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110147792-A1 Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device CCNE2, CCNE1, CCNT1 ESR1 32/4885ESR2 216/4885ALOX5 1235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.